Deutsch English Français

Contact

EP4088739

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP4088739

EP4088739 - METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 14.10.2022 Database last updated on 15.06.2024
Former	The international publication has been made Status updated on 07.07.2021
Most recent event Tooltip	27.12.2023	New entry: Renewal fee paid
Applicant(s)	For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP
	[N/P]
Former [2022/46]	For all designated states Eisai R&D Management Co., Ltd. 4-6-10 Koishikawa Bunkyo-ku Tokyo 112-8088 / JP
Inventor(s)	01 / MATSUO Kimihiro C/O Eisai Co., Ltd. Kashima Plant, 22, Sunayama Kamisu-shi, Ibaraki 314-0255 / JP
	02 / NAKAMURA Taiju C/O Eisai Co., Ltd. Kashima Plant, 22, Sunayama Kamisu-shi, Ibaraki 314-0255 / JP
	03 / MIYASHITA Yusuke C/O Eisai Co., Ltd. Kashima Plant, 22, Sunayama Kamisu-shi, Ibaraki 314-0255 / JP
	[2022/46]
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2022/46]
Application number, filing date	20905452.7	21.12.2020
	[2022/46]
	WO2020JP47706
Priority number, date	JP20190231938	23.12.2019 Original published format: JP 2019231938
	[2022/46]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2021132166
	Date:	01.07.2021
	Language:	JA
	[2021/26]
	Type:	A1 Application with search report
	No.:	EP4088739
	Date:	16.11.2022
	Language:	EN
	[2022/46]
Search report(s)	International search report - published on:	JP	01.07.2021
Classification	IPC:	A61K39/395, A61P35/00, C07K5/062, C07K16/28, A61K47/68, C12N15/13, A61K31/357	[2022/46]
	CPC:	A61P35/00 (EP,IL,KR); A61K31/357 (IL,KR); A61K47/6803 (EP,KR,US); A61K47/6849 (US); A61K39/395 (IL); A61K47/545 (US); (+) A61K47/68 (IL); A61K47/6889 (EP); C07K16/00 (IL,KR); C07K16/28 (EP,IL,KR); C07K5/06017 (IL,KR); C07K5/06052 (EP) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/46]
Extension states	BA	30.06.2022
	ME	30.06.2022
Validation states	KH	30.06.2022
	MA	30.06.2022
	MD	30.06.2022
	TN	30.06.2022
Title	German:	VERFAHREN ZUM PRODUZIEREN EINES ERIBULINBASIERTEN ANTIKÖRPER-WIRKSTOFFKONJUGATS	[2022/46]
	English:	METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATE	[2022/46]
	French:	PROCÉDÉ DE PRODUCTION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT À BASE D'ÉRIBULINE	[2022/46]
Entry into regional phase	30.06.2022	Translation filed
	30.06.2022	National basic fee paid
	30.06.2022	Search fee paid
	30.06.2022	Designation fee(s) paid
	30.06.2022	Examination fee paid
Examination procedure	30.06.2022	Examination requested [2022/46]
	14.04.2023	Amendment by applicant (claims and/or description)
Fees paid	Renewal fee
	27.12.2022	Renewal fee patent year 03
	27.12.2023	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y]WO03062375 (GENENTECH INC [US]) [Y] 2-5* fig. 1A, 1B *;
		[XY]WO2013072813 (PFIZER [US]) [X] 8 * pp. 79-80, page 108, lines 11-23, page 111, lines 29-30 pp. 79-80, page 108, lines 11-23, page 111, lines 29-30 * [Y] 1-7;
		[Y]WO2014205342 (MORPHOTEK INC [US]) [Y] 2-5 * paragraph [0081] SEQ ID NO: 41, 46, paragraph [0089] SEQ ID NO: 7, 8 *;
		[XY]WO2016151432 (PFIZER [US]) [X] 8 * p. 97 p. 97 * [Y] 1-7;
		[Y]WO2017151979 (EISAI INC [US], et al) [Y] 1-7 * claims, paragraph [0013] *;
		[XY]WO2018200812 (NOVARTIS AG [CH], et al) [X] 8 * page 556, examples 1-5 page 556, examples 1-5 * [Y] 1-7;
		[XY]WO2019232449 (EISAI R&D MAN CO LTD [JP]) [X] 8 * paragraph [1010] paragraph [1010] * [Y] 1-7;
		[XY] - Cazzamalli Samuele, Figueras Eduard, Pethő Lilla, Borbély Adina, Steinkühler Christian, Neri Dario, Sewald Norbert, "In Vivo Antitumor Activity of a Novel Acetazolamide-Cryptophycin Conjugate for the Treatment of Renal Cell Carcinomas", ACS Omega, (20181102), vol. 3, no. 11, ISSN 2470-1343, pages 14726 - 14731, XP055838198 [X] 8 * , page 14727, scheme 1 page 14727, scheme 1 page 14727, scheme 1 * [Y] 1-7 DOI: http://dx.doi.org/10.1021/acsomega.8b02350
	by applicant	US4816567
		WO9005144
		US5821337
		WO2006034488
		WO2017151979
		- MUKHTAR et al., Mol. Cancer Ther., (20140000), vol. 13, pages 275 - 84
		- DUMONTETJORDAN, Nat. Rev. Drug Discov., (20100000), vol. 9, pages 790 - 803
		- O'SHANNESSY et al., Int. J. Gynecol. Pathol., (20130000), vol. 32, no. 3, pages 258 - 68
		- CHRISTOPH et al., Clin. Lung Cancer, (20140000), vol. 15, no. 5, pages 320 - 30
		- KING et al., Science, (19850000), vol. 229, pages 974 - 6
		- SLAMON et al., Science, (19890000), vol. 244, pages 707 - 12
		- GAJRIACHANDARLAPATY, Expert Rev. Anticancer Ther., (20110000), vol. 11, pages 263 - 75
		- O' SHANNESSY et al., Oncotarget, (20110000), vol. 2, pages 1227 - 43
		- FENGDOOLITTLE, J. Mol. Evol., (19870000), vol. 35, pages 351 - 60
		- KOHLER et al., Nature, (19750000), vol. 256, page 495
		- CLACKSON et al., Nature, (19910000), vol. 352, pages 624 - 8
		- MARKS et al., J. Mol. Biol., (19910000), vol. 222, pages 581 - 97
		- WARD et al., Nature, (19890000), vol. 341, pages 544 - 6
		- BIRD et al., Science, (19880000), vol. 242, pages 423 - 6
		- HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 83
		- HE et al., J. Nucl. Med., (20100000), vol. 51, pages 427 - 32
		- FITTING et al., MAbs, (20150000), vol. 7, pages 390 - 402
		- HOLLIGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 5873 - 87
		- POLJAK et al., Structure, (19940000), vol. 2, pages 1121 - 3
		- "NCBI", Database accession no. NP 004439.2
		- HAGER-BRAUNTOMER, Expert Rev. Proteomics, (20050000), vol. 2, pages 745 - 56
		- PEARSON, LIPMAN, Proc. Nat. Acad. Sci. USA, (19880000), vol. 85, page 2444
		- TZARTOS, Methods in Molecular Biology, (19980000), vol. 66, pages 55 - 66
		- EBEL et al., Cancer Immunity, (20070000), vol. 7, page 6
		- LYON et al., Methods Enzymol., (20120000), vol. 502, pages 123 - 38
		- DUBOWCHIK et al., Bioconjugate Chem, (20020000), vol. 13, pages 855 - 69
		- JAIN et al., Pharm. Res., (20150000), vol. 32, pages 3526 - 40
		- SIMON et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, page 9367
		- SMITHWATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482
		- NEEDLEMAN, WUNSCH, J. Mol. Biol., (19700000), vol. 48, page 443
		- DEVEREUX et al., Nucl. Acid Res., (19840000), vol. 12, pages 387 - 95
		- "Current Methods in Sequence Comparison and Analysis", Macromolecule Sequencing and Synthesis, Selected Methods and Applications, Alan R. Liss, Inc, (19880000), pages 127 - 149
		- HIGGINSSHARP, CABIOS, (19890000), vol. 5, pages 151 - 3
		- ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, pages 403 - 10
		- ALTSCHUL et al., Nucleic Acids Res., (19970000), vol. 25, pages 3389 - 402
		- ALTSCHUL et al., Methods in Enzymology, (19960000), vol. 266, pages 460 - 80
		- ALTSCHUL et al., Nucl. Acids Res., (19930000), vol. 25, pages 3389 - 402

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p